Streetwise Reports' Article Archives — February 2018 back to current month (10)
Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market' (02/23/2018)
Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential.
Fund Manager Names Three Small-Caps with Strong Growth Profiles (02/22/2018)
The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects.
Can a Simple Test Really Predict Whether a Cancer Treatment Will Succeed? (02/20/2018)
Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma.
Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple (02/20/2018)
One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine."
Medical Device Firm to Launch Trials for Treatment Targeting $12 Billion Incontinence Market (02/14/2018)
Anthony Vendetti, an analyst with Maxim Group, shared the results both of a pilot study for stress urinary incontinence and of a recent equity raise by this company.
Biotech with Tenbagger Potential Signs Deal with Chinese Firm (02/14/2018)
Joseph Pantginis, an analyst with H. C. Wainwright & Co., detailed prospects for this biopharmaceutical corporation's new partnership with an Asian biotech and other near-term plans.
Company Takes Aim at Approval of Colorectal Cancer Screening Test in EU (02/13/2018)
Two analysts take note as this biotech prepares to release data on its colorectal cancer screening product.
The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle (02/12/2018)
Ron Struthers of Struthers Resource Stock Report discusses recent trends in cannabis investing and profiles a handful of cannabis companies.
Oncology Biotech with Precision Medicine Focus Added to Analyst's 2018 Top-Pick List (02/07/2018)
A small-cap biotech focused on developing customized treatments for cancer patients has earned inclusion on the NASDAQ Biotechnology Index, as well as caught the eye of analyst Michael King of JMP Securities.
Immuno-oncology Pure Play 'Ideally Positioned to Capture Value' (02/07/2018)
Maxim Group analyst Jason McCarthy explained why investors should focus on this emerging technology and one developer that is well-positioned to capture value in the space.
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec